Table 1.

Summary of preclinical assessments of galectin-1 delivery to treat T-cell-dependent immunopathologies

Immunopathology model	Host	Outcome	References
Graft-versus-host disease	Mouse	Increased numbers of splenic B cells and CD4 + T cells, decreased IL-2 and IFN-y release, decreased host alloreactivity	Baum et al.52
Collagen-induced osteoarthritis	Mouse	Decreased proinflammatory cytokine release, decreased anticollagen IgG titers, Th2-skewed antigen immune response	Rabinovich et al.53
Experimental colitis	Mouse	Decreased numbers of hapten-activated T cells, decreased proinflammatory cytokine release, increased numbers of apoptotic mononuclear cells within colon	Santucci et al.54
Experimental autoimmune encephalomyelitis	Mouse	Increased microglia deactivation, decreased axonal damage, decreased demyelination, decreased neuronal degeneration	Starossom et al.55
Experimental autoimmune uveitis	Mouse	Increased T cell apoptosis, decreased antigen-specific IgG titers, decreased leukocyte infiltrate, Th2 orTreg-skewed immune response	Toscano et al.56
Renal allogeneic transplant	Rat	Increased recipient animal survival, decreased serum IFN-y and soluble CD30, decreased CD8 + T cell-mediated cytotoxicity	Xu et al.57